drugset / Trial / NCT06070948

A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female Participants

NCT06070948 ↗

Phase 1 Withdrawn AbbVie
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to assess the bioavailability of two different doses of venetoclax new high drug load formulation tablets relative to two tablets of the currently marketed venetoclax tablets under fed conditions.

Timeline

Start
2023-10-05
Primary completion
2025-07-28
Completion
2025-07-28

Outcome

Outcome not reported

Stopped (Business): “Strategic considerations”

Drugs

EvaluationDrugModalityDoseRoute
Subject Venetoclax Small molecule — Oral

Indications

No indication recorded.